18 terminated. 18 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Terminated 18 |
| Phase 1 | 5 | Terminated 5 |
| Phase 3 | 1 | Terminated 1 |
Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 Nitazoxanide, Placebo Nitazoxanide, Ribavirin - SARS-CoV Infection, Covid19 | Phase 2 | Terminated | Rutgers, The State University of New Jersey | 7 | 2020-12-02 | 2022-05-05 |
| A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Brequinar/Brequinar + Ribavirin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Clear Creek Bio, Inc. | 17 | 2018-12-20 | 2022-08-08 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) Uprifosbuvir, Ruzasvir, Ribavirin - Hepatitis C | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 282 | 2016-11-16 | 2021-02-02 |
| 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C | Phase 2 | Terminated | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 7 | 2016-02-17 | 2018-05-02 |
| Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) MK-3682B, Ribavirin - Hepatitis, Hepatitis C | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 94 | 2015-12-10 | 2024-05-22 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV) - HIV Infections, Hepatitis C | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2015-09-16 | 2021-11-04 |
| Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C Ribavirin, Hydroxychloroquine - Hepatitis C | Phase 1 / Phase 2 | Terminated | BioLineRx, Ltd. | 4 | 2013-04-01 | 2014-08-28 |
| An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C | Phase 1 / Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 42 | 2013-01-01 | 2016-07-20 |
| Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a - Hepatitis C | Phase 2 | Terminated | Bristol-Myers Squibb | 210 | 2012-05-01 | 2015-11-04 |
| An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a - Hepatitis C | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 61 | 2012-02-01 | 2015-06-18 |
| Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) Grazoprevir, Placebo to Grazoprevir, Peginterferon alfa-2b (Peg-IFN) - Hepatitis C, Chronic | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 5 | 2011-11-28 | 2024-05-22 |
| Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Ribavirin - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Jewish General Hospital | 5 | 2011-03-17 | 2025-07-29 |
| Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders CTS-1027, pegylated interferon, Ribavirin - Hepatitis C | Phase 2 | Terminated | Conatus Pharmaceuticals Inc. | 114 | 2011-01-01 | 2012-06-11 |
| A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection telaprevir, VX-222, ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 152 | 2010-08-01 | 2020-09-30 |
| Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia romiplostim, ribavirin, placebo - Hepatitis C Infection, Thrombocytopenia | Phase 2 | Terminated | University of Southern California | 27 | 2010-06-30 | 2017-04-11 |
| Treatment With Ribavirin for Patients With Metastatic Breast Cancer Ribavirin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Jewish General Hospital | 4 | 2009-12-01 | 2015-11-04 |
| Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis Ribavirin, Colchicine - Chronic Hepatitis C | Phase 2 | Terminated | Hospital Universitario Ramon y Cajal | 50 | 2009-01-01 | 2013-01-31 |
| Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) Boceprevir, Narlaprevir, Peginterferon alfa-2b - Hepatitis C, Chronic, Hepacivirus | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1954 | 2007-02-20 | 2018-09-11 |
Hepatitis C (10) · Hepatitis C, Chronic (3) · Breast Neoplasms (1) · COVID-19 (1) · Digestive System Diseases (1) · Flaviviridae Infections (1) · HIV Infections (1) · Hepatitis (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Leukemia, Myeloid, Acute (1) · Liver Diseases (1) · RNA Virus Infections (1) · Severe Acute Respiratory Syndrome (1) · Thrombocytopenia (1)
Merck Sharp & Dohme LLC (4) · Vertex Pharmaceuticals Incorporated (3) · Jewish General Hospital (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · BioLineRx, Ltd. (1) · Bristol-Myers Squibb (1) · Clear Creek Bio, Inc. (1) · Conatus Pharmaceuticals Inc. (1) · Hospital Universitario Ramon y Cajal (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Rutgers, The State University of New Jersey (1) · University of Southern California (1)
United States (10) · Canada (3) · Spain (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Puerto Rico (1) · United Kingdom (1)
Annie Luetkemeyer, MD (1) · Erin Castelloe, MD (1) · Howard Liebman (1) · Jeffrey L Carson, MD (1) · Jennifer J. Kiser, PharmD (1) · Katherine Borden, PhD (1) · Marc Bourliere, MD (1) · Mark S. Sulkowski, MD (1) · Stanislas Pol, MD (1)
PMID 24901821, PMID 24982088, PMID 27219495, PMID 28688129, PMID 29091342, PMID 31108015, PMID 32406487
2015 (1), 2016 (1), UM1AI068636 (1)